Literature DB >> 7513761

Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine.

J Ojwang1, A Elbaggari, H B Marshall, K Jayaraman, M S McGrath, R F Rando.   

Abstract

Oligonucleotide compounds composed of only deoxyguanosine and deoxythymidine were able to significantly inhibit human immunodeficiency virus type -1 (HIV-1)-induced syncytium formation and virus production (as measured by p24 core antigen expression) in an acute infection assay system. The oligonucleotides did not share any homology with or possess any complementary (antisense) sequence motifs to the HIV-1 genome. The guanosine/thymidine-containing oligonucleotides (GTOs) that showed this anti-HIV activity contained natural phosphodiester (PD) linkages (backbones) between the nucleosides. One of the PD oligonucleotide sequence motifs tested was capable of inhibiting HIV-1-induced syncytium formation and p24 production with a median effective dose in culture (ED50) in the submicromolar range. In addition, oligonucleotides tested were able to significantly suppress HIV-1 p24 levels > or = 7 days after removal of the drug from the infected cell culture medium. The growth inhibition properties (toxicity) of this genre of oligonucleotides was determined to be well above the ED50 values yielding high selective indexes. In vitro results showed that GTOs with PD backbones were potent competitive inhibitors of HIV-1 reverse transcriptase. These same molecules were capable of blocking the interaction between gp120 and CD4. All measured activities of these molecules were increased by factors of 10-500 when the PD backbone was replaced with a PT backbone in a sequence-dependent manner. The enhanced antiviral activity displayed by the sulfur group on the oligonucleotide backbone and the lack of any sequence-specific interactions suggest that a percentage of antiviral activity of oligonucleotide-based therapeutics is due to mechanisms other than those originally postulated for oligonucleotides. The good selective index of GTOs coupled with the prolonged suppression of HIV-1 in culture after removal of oligonucleotides from the infected cell culture make this a class of compounds that warrant investigation as therapeutic agents to be used against HIV-1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513761

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  12 in total

1.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

Review 3.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide.

Authors:  V Prasad; S Hashim; A Mukhopadhyay; S K Basu; R P Roy
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Native oligodeoxynucleotides specifically active against human immunodeficiency virus type 1 in vitro: a G-quartet-driven effect?

Authors:  L Tondelli; F P Colonna; A Garbesi; S Zanella; M E Marongiu; S Corrias; A G Loi; P La Colla
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Inhibition of human immunodeficiency virus type 1 activity in vitro by a new self-stabilized oligonucleotide with guanosine-thymidine quadruplex motifs.

Authors:  Jun-ichiro Suzuki; Naoko Miyano-Kurosaki; Tomoyuki Kuwasaki; Hiroaki Takeuchi; Gota Kawai; Hiroshi Takaku
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles.

Authors:  M Berton; P Turelli; D Trono; C A Stein; E Allémann; R Gurny
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

8.  T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.

Authors:  J O Ojwang; R W Buckheit; Y Pommier; A Mazumder; K De Vreese; J A Esté; D Reymen; L A Pallansch; C Lackman-Smith; T L Wallace
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides.

Authors:  Z Khaled; L Benimetskaya; R Zeltser; T Khan; H W Sharma; R Narayanan; C A Stein
Journal:  Nucleic Acids Res       Date:  1996-02-15       Impact factor: 16.971

10.  Mechanism of inhibition of HIV-1 infection in vitro by guanine-rich oligonucleotides modified at the 5' terminal by dimethoxytrityl residue.

Authors:  H Furukawa; K Momota; T Agatsuma; I Yamamoto; S Kimura; K Shimada
Journal:  Nucleic Acids Res       Date:  1994-12-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.